Lung deposition of inhaled once-daily long-acting muscarinic antagonists standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease
Background: Data for bronchodilator deposition via nebulizers and dry powder inhalers (DPIs) in the respiratory tract of patients with chronic obstructive pulmonary disease (COPD) are limited. We used functional respiratory imaging (FRI) to determine deposition patterns for revefenacin solution via...
Main Authors: | Glenn D. Crater, Karmon Johnson, Jonathan Ward, Jan De Backer |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-03-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/17534666221077561 |
Similar Items
-
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
by: James F. Donohue, et al.
Published: (2020-05-01) -
Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01) -
The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro
by: Maria Gabriella Matera, et al.
Published: (2024-02-01) -
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
by: Ulrik CS
Published: (2012-09-01) -
Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
by: Eung Gu Lee, et al.
Published: (2023-05-01)